OraSure’s MIRIAD results
This article was originally published in The Gray Sheet
Executive Summary
OraQuick rapid HIV test use in point-of-care labor and delivery settings allows an average 45 minute turn-around time - more than four times faster than the 3.5 hour average needed when the same test is performed in a lab, according to CDC's Maternal Infant Rapid Intervention at Delivery study. Started in November 2001, MIRIAD tested 380 women in Chicago with 100% accuracy, finding and treating three who were HIV positive. OraQuick was approved by FDA in November 2002. CDC's previous purchase of 250,000 of the tests will be finalized in January (1"The Gray Sheet" June 30, 2003, In Brief)...
You may also be interested in...
OraSure OraQuick
CDC commits to purchase of 250,000 rapid HIV-1 antibody tests for $2 mil. by Dec. 31 for 50 U.S. locations. Approved in November 2002 and CLIA-waived in January, the test will be used in CDC's HIV testing and prevention initiative. The Bethlehem, Penn. firm donated tests to eight sites for "national HIV testing day" June 27...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.